You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,666,832


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,666,832
Title:Methods of treatment using specific binding agents of human angiopoietin-2
Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
Inventor(s): Oliner; Jonathan Daniel (Newbury Park, CA), Min; Hosung (Newbury Park, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:11/499,903
Patent Claims:1. A method for treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a peptide or peptibody capable of binding Ang-2, wherein the peptide or peptibody comprises at least one amino acid sequence selected from the group consisting of SEQ ID NO: 6, and SEQ ID NO: 119 to SEQ ID NO: 142, inclusive, and physiologically acceptable salts thereof.

2. A method for treating an inflammatory disease which comprises administering to a patient in need thereof a therapeutically effective amount of a composition of matter of the formula: (X.sup.1).sub.a-F.sup.1-(X.sub.2).sub.b and multimers thereof, wherein: F.sup.1 is a vehicle; X.sup.1 X.sup.2 are each independently selected from -(L.sup.1).sub.c-P.sup.1; -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2; -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.sup.3; and -(L.sup.1).sub.c-P.sup.1-(L.sup.2).sub.d-P.sup.2-(L.sup.3).sub.e-P.su- p.3-(L.sup.4).sub.f-P.sup.4; wherein a, b, c, d, e and fare each independently 0 or 1, provided that at least one of a and b is 1; wherein L.sup.1, L.sup.2, L.sup.3, and L.sup.4 are each independently linkers; and wherein one or more of P.sup.1, P.sup.2, P.sup.3, and P.sup.4 each independently comprise a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 6 and SEQ ID NOS: 119-142, inclusive; and physiologically acceptable salts thereof.

3. The method according to claim 1 further comprising administering at least one anti-inflammatory agent.

4. The method according to claim 3 wherein the anti-inflammatory agent comprises at least one of a disease modifying anti-rheumatic drug (DMARD), slow acting anti-rheumatic drug (SAARD), and non-steroidal anti-rheumatic drug (NSAID).

5. The method according to claim 3 wherein the anti-inflammatory agent comprises at least one of methotrexate, a TNF inhibitor, a IL-1 inhibitor, a TACE inhibitor, a COX-2 inhibitor, and a P-38 inhibitor.

6. The method according to claim 5 wherein the TNF inhibitor comprises at least one of etanercept, adalimumab, pegsunercept sTNF-R1, onercept, and infliximab.

7. The method according to claim 5 wherein said IL-1 inhibitor is at least one of anakinra, IL-1 TRAP, IL-1 antibody, and soluble IL-1 receptor.

8. The method according to claim 3 wherein the administration is concurrent administration.

9. The method according to claim 3 wherein the administration is non-concurrent administration.

Details for Patent 7,666,832

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2021-10-11
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2021-10-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.